ArticleBMC complementary medicine and therapies2025
Antioxidant and cytotoxic properties of protocorm-derived phenol-rich fractions of Dendrobium amoenum.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDendrobium amoenum is known for its aesthetic and medicinal values but it is threatened due to loss of wild resources. Plant tissue culture promotes wild resource protection and paves the way for secondary metabolite production. In this study, protocorms developed via in-vitro seed cultivation were used for bioactive secondary metabolite production. The objectives of this study were to evaluate total phenolic and flavonoid contents, to identify the bioactive secondary metabolites, to explore the antioxidants and cytotoxic properties of in-vitro-derived protocorms extracts of D. amoenum.
methodsSeeds of D. amoenum were cultivated on 10% coconut water, 0.25 and 0.5 mg/L BAP supplemented full-strength and half-strength MS medium to produce protocorms for the isolation of bioactive components. A distinct yellow fraction (DAYF), light-green fraction (DALGF), green fraction (DAGF), and dark-green fraction (DADGF) were obtained from methanol extract on a methanol-based Sephadex LH-20 column. The total phenol and flavonoid contents along with the antioxidant and cytotoxic properties of the fractions were evaluated. The compounds in active DAYF were identified using a GC-MS.
resultsOn a full-strength solid MS medium supplemented with 10% coconut water, approximately 95% of the seeds grew into protocorms, while 88.33% did so on a full-strength liquid MS medium. The DAYF had a total phenol content of 206.38 μg of GAE and a total flavonoid content of 101.88 μg of QE. Owing to these high contents, the DAYF inhibited 50% of the DPPH free radicals at a concentration of 63.73 μg/ml. Similarly, it also reduced the growth of HeLa cells by 50% at 67.03 μg/ml and U2OS cells by 50% at 207.40 μg/ml, while it was nontoxic to normal human epithelium cells. Bioactive phenolic compounds 2-methoxy-4-vinylphenol (1), 3,4-dimethoxy-phenol (2), 2-methoxy-4-(1-propenyl)-phenol (3), 2,6-dimethoxy-4-(2-propenyl)-phenol (4), 3-methoxy-1,2-benzenediol (5) were identified in the DAYF.
conclusionProtocorms of D. amoenum could serve as sources of bioactive secondary metabolites highlighting their potential in alternative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.